Literature DB >> 2979230

Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis.

R A van Hogezand1, P A van Hees, J P van Gorp, H J van Lier, J H Bakker, P Wesseling, U J van Haelst, J H van Tongeren.   

Abstract

Suppositories containing 300 mg 5-aminosalicylic acid (1.96 mmol) or 425 mg acetyl-5-aminosalicylic acid (1.96 mmol) were used in 40 patients with idiopathic proctitis to determine the efficacy of acetyl-5-aminosalicylic acid in treating this bowel inflammation. Each patient was treated with 5-aminosalicylic acid or acetyl-5-aminosalicylic acid suppositories twice daily for 4 weeks in a double-blind trial. Four patients were included twice in the trial. The second time they were treated with the alternative regimen. Six patients in the acetyl-5-aminosalicylic acid group did not complete the trial, four of them because of diarrhoea. Complete clinical remission with normal rectal mucosa on sigmoidoscopy was achieved in 10 out of 18 patients on 5-aminosalicylic acid and in only two out of 15 in the acetyl-5-aminosalicylic acid group (P = 0.03). A favourable histological improvement was demonstrated with 5-aminosalicylic acid suppositories, but the difference with acetyl-5-aminosalicylic acid was not significant (P = 0.059). Three of the four patients who received both drugs recovered with 5-aminosalicylic acid; in none of them was acetyl-5-aminosalicylic acid effective. The results from this study and from previous investigations show that acetyl-5-aminosalicylic acid is not superior to placebo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2979230     DOI: 10.1111/j.1365-2036.1988.tb00668.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  16 in total

Review 1.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

2.  Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions cultured under aerobic and anaerobic conditions.

Authors:  R A van Hogezand; H M Kennis; A van Schaik; J P Koopman; P A van Hees; J H van Tongeren
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.

Authors:  L Staerk Laursen; M Stokholm; K Bukhave; J Rask-Madsen; K Lauritsen
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

5.  Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.

Authors:  F N Hussain; R A Ajjan; S A Riley
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

6.  Mesalazine release from coated tablets: effect of dietary fibre.

Authors:  S A Riley; I A Tavares; P M Bishai; A Bennett; V Mani
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

7.  Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2.

Authors:  Verónica Ramírez-Alcántara; Marshall H Montrose
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-17       Impact factor: 4.052

8.  What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

Authors:  S A Riley
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

9.  Comparison of 5-aminosalicylic acid and N-acetylaminosalicylic acid uptake by the isolated human colonic epithelial cell.

Authors:  A Ireland; J D Priddle; D P Jewell
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

10.  Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations.

Authors:  M De Vos; H Verdievel; R Schoonjans; M Praet; M Bogaert; F Barbier
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.